Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
| 대상 질환 | Atrial Fibrillation, Stroke, Bleeding |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Massachusetts General Hospital |
| 상태 | 완료 |
| 참여자 수 | 100 명 |
| 중재(약물) | Rivaroxaban, Warfarin |
| 시작일 | 2019년 4월 30일 |
| 완료일 | 2023년 10월 1일 |
| 결과 공개일 | 2026년 5월 19일 |
요약
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.
Postoperative Length of Stay
| Warfarin | 8 days |
|---|---|
| Rivaroxaban | 7 days |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
- Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
- Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
- Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
- Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.
- Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintai — Ottawa Heart Institute Research Corporation